The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
LEAP was created in 2003 to strengthen clinical research capacity and serve as a base for training
Abstract
Visceral leishmaniasis is a neglected tropical disease endemic in East Africa where improved patient-adapted treatments are needed. The Leishmaniasis East Africa Platform (LEAP) was created in 2003 to strengthen clinical research capacity, serve as a base for training, and evaluate and facilitate implementation of new treatments. Major infrastructure upgrades and personnel training have been carried out. A short course of Sodium Stibogluconate and Paramomycin was evaluated and is now first-line treatment in the region; alternative treatments have also been assessed.
LEAP can serve as a successful model of collaboration between different partners and countries when conducting clinical research in endemic countries to international standards.
This research is part of the Drugs for Neglected Diseases initiative (DNDi)
Citation
Wasunna M, Musa, A, Hailu A, Khalil EAG, Olobo J, Juma R, Wells S, Alvar J, Balasegaram M. (2016) The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. Transactions of The Royal Society of Tropical Medicine and Hygiene, Volume 110, Issue 6, 1 June 2016, Pages 321–323, https://doi.org/10.1093/trstmh/trw031